NSCLC | Meet The Professor: Non-Small Cell Lung Cancer with an Actionable Target Beyond EGFR — Part 2

Featuring perspectives from Dr Justin Gainor, including the following topics: Introduction (0:00) Immunotherapy for Patients with Targetable Mutations (8:02) Case: A man in his early 80s with recurrent, localized spindle cell carcinoma of the lung, PD-L1 of 40% — Kapisthalam (KS) Kumar, MD (16:03) Case: A woman in her late 50s with microsatellite-stable adenocarcinoma of the lung with an NRG1 fusion — Ranju Gupta, MD (26:57) Case: A woman in her late 50s with metastatic PD-L1-negative adenocarcinoma of the lung and a RET KF5B fusion — Neil Morganstein, MD (32:13) Case: A woman in her early 70s with Stage IIB adenocarcinoma of the lung and an ALK rearrangement, PD-L1 of 5% — Susannah Friemel, MD (37:17) Cases: A woman in her early 50s with metastatic NSCLC and an ALK (2p23) rearrangement, PD-L1 tumor proportion score of 50%; a man in his mid 60s with metastatic adenocarcinoma of the lung involving the brain, an ALK rearrangement and PD-L1 of 20% — Daniel R Carrizosa, MD, MS (41:52) Case: A man in his late 60s with metastatic adenocarcinoma of the lung and a HER2 V659D mutation — Spencer Henick Bachow, MD (47:49) CME information and select publications